Serina Therapeutics IncSER
Price$1.95

Outlook & Key Dates

Estimates, guidance, catalysts, and upcoming events

Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
18.0%projected annual EPS growth
As of 27 Aug 2026
Analyst Coverage
2analysts covering
As of 18 Aug 2026
FY EPS (est.)
-$1.41next fiscal year
As of 18 Aug 2026
Monitoring Framework
Key Performance Indicators
SER-252 Phase 1b Clinical Trial Enrollment QuarterlyTarget: Complete enrollment and dosing of Cohort 1
Cash and Cash Equivalents Quarterly24.5MTarget: Fund operations through key clinical milestones
Watch Items
  • SER-252 Single-Ascending-Dose (SAD) Topline ResultsTrigger: First Half of 2027Action: Review safety, tolerability, and pharmacokinetics data to support registrational pathway
  • NYSE American Continued Listing ComplianceTrigger: Compliance Plan AcceptanceAction: Monitor execution of the accepted compliance plan to maintain listing status
Sign in / Sign up to read more

Research as of 20 Jun 2026

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.